XML 15 R4.htm IDEA: XBRL DOCUMENT v3.25.2
Consolidated Statements of Operations (Unaudited) - USD ($)
 3 Months Ended 6 Months Ended
Jun. 30, 2025
Jun. 30, 2024
Jun. 30, 2025
Jun. 30, 2024
Revenues:        
Revenues $ 4,000 $ 33,000
Operating expenses:        
Research and development 68,000 2,023,000 890,000 4,825,000
General and administrative 1,249,000 1,625,000 5,463,000 3,207,000
Total operating expenses 1,317,000 3,648,000 6,353,000 8,032,000
Operating loss (1,317,000) (3,644,000) (6,353,000) (7,999,000)
Other expense:        
Foreign exchange losses (3,000) 3,000 (11,000) 4,000
Interest income 2,000 (28,000) 8,000 (26,000)
Gain on deconsolidation of subsidiary 4,947,000
Other income, net 2,000 12,000 52,000
Total other income (expense), net 1,000 (25,000) 4,956,000 30,000
Loss before taxes (1,316,000) (3,669,000) (1,397,000) (7,969,000)
Income tax benefit (2,000) 412,000 (2,000) 1,766,000
Net loss (1,318,000) (3,257,000) (1,399,000) (6,203,000)
Dividend on convertible exchangeable preferred shares (20,000) (20,000)
Net loss applicable to common shareholders $ (1,338,000) $ (3,257,000) $ (1,419,000) $ (6,203,000)
Basic and diluted earnings per common share:        
Net loss per share, basic $ (0.98) $ (172.18) $ (1.62) $ (509.96)
Net loss per share, diluted $ (0.98) $ (172.18) $ (1.62) $ (509.96)
Clinical Trial Supply [Member]        
Revenues:        
Revenues $ 4,000 $ 33,000